Posted by Michael Wonder on 17 Jan 2026
US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
15 January 2026 - The US FDA has delayed reviews of two drugs chosen for the Trump Administration's new fast track program after agency scientists flagged safety and efficacy concerns, including the death of a patient while taking one of the medicines, internal documents seen by Reuters show.
FDA reviewers pushed back by two weeks Disc Medicine's new tab experimental drug for a rare blood disorder following concerns about trial data and its risk for abuse.
